期刊文献+

结肠癌组织ERCC1基因多态性与奥沙利铂药敏关系 被引量:1

The Relationship between ERCC1 Gene Polymorphism in Colorectal Cancer and the Sensitivity to Oxaliplatin Chemotherapy
原文传递
导出
摘要 [目的]探讨结肠癌组织ERCC1密码子118基因多态性与奥沙利铂药敏的关系。[方法]对53例结肠癌患者新鲜标本进行体外肿瘤细胞原代培养,ATP-TCA法检测肿瘤细胞对奥沙利铂的敏感性,PCR法检测肿瘤的ERCC1密码子118基因多态性,分析ERCC1密码子118基因多态性与奥沙利铂敏感性的关系。[结果]奥沙利铂总有效率为34.7%(17/49)。C/C基因组19例,有效10例,无效9例,有效率52.6%;C/T+T/T基因组30例,有效7例,无效23例,有效率23.3%。ERCC1不同基因型组间对奥沙利铂敏感性存在显著性差异(P<0.05)。[结论]ERCC1基因多态性与奥沙利铂化疗敏感性相关,ERCC1基因型检测可能有助于预测结肠癌组织对奥沙利铂化疗敏感性。
出处 《肿瘤学杂志》 CAS 2011年第12期900-902,共3页 Journal of Chinese Oncology
基金 江西省科技厅支撑计划资助项目(2010BSB00503)
  • 相关文献

参考文献8

  • 1Ahaha R, Liang X,Yu JJ, et al. Excision repair cross com- plementing-group l:gene expression and platinum resis- tance [J]. Int J Mol Med, 2004,14(6):959-970.
  • 2Kurbacher CM, Cree IA, Bruckner HW, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer[J]. Anticancer Drugs, 1998, 9 (1):51-57.
  • 3Su D,Ma S,Liu P,et al.Genetic polymorphisms and treat- ment response in advanced non-small cell lung cancer[J]. Lun Cancer, 2007, 56(2):281-288.
  • 4温钦生,李邦华.结直肠癌组织中ERCC1表达与奥沙利铂耐药的研究进展[J].江西医药,2010,45(3):260-263. 被引量:6
  • 5Kawashima A,Nakayama M,Kakuta Y , et al. Excision re- pair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer[J]. Clin Cancer Res,2011, 17(8):2561-2569.
  • 6Kim SH, Kwon HC, Oh SY , et al.Prognostic value of ER- CC1, thymidylate synthase, and glutathione S-transferase pi for 5-Fuoxaliplatin chemotherapy in advanced colorec- tal cancer[J]. Am J Clin Oncol, 2009, 32(1):38-43.
  • 7Chang PM, Tzeng CH, Chen PM,et al. ERCC1 codon 118 CT polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma [J].Cancer Sei, 2009,100(2):278-283.
  • 8Huang MY, Huang ML, Chen MJ,et al. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy [J]. Pharmacogenet Genomics, 2011, 21(1):18-25.

二级参考文献17

  • 1Wilson MD,Ruttan CC,Koop BF,et al.ERCC1:a comparative genomic perspective.Environ Mol Mutagen,2001,38(2-3):209.
  • 2Ali Z.Al Minawi,Yin Fai Lee,et al.The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cress-links.Nucleic Acids Res,2009,37(19):6400.
  • 3Abbasi R,Ramroth H,Becher H,et al.Polymorphisms of DNA repair genes and risk of non-small cell lung cancer.Carcinogenesis,2006,27(3):560.
  • 4Hector.S,Bolanowska-Higdon W,Zdanowicz J,et al.In vitro studies on the mechanisms of oxaliplatin resistance.Cancer Chemother Pharmacol,2001,48(5):398.
  • 5Arnould S,Hennebelle I,Canal P,et al.Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.Eur J Cancer,2003,39(1):112.
  • 6Balin Ganthier D,Delord JP,Pillaire MJ,et al.Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.Br J Cancer,2008,98(1):120.
  • 7Paré L,Marcuello E,Altés A,et al.Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.Br J Cancer,2008,99(7):1050.
  • 8Kim SH,Kwou HE,Oh SY,et al.Prognostic value of ERCC1,thymidylate synthase,and glutathioue S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.Am J Clin Oncol,2009,32(1):38.
  • 9Ruzzo A,Graziano F,Loupakis F,et al.Pharmacogenetic profiling in patients with advanced calorectal cancer treated with first-line FOLFOX-4 chemotherapy.Erratum in:J Clin Oncol,2009,27(19):3262.
  • 10Park DJ,Zhang W,Stoehlmacher J,et al.ERCC1 gene polymorphism as a predictor for clinical outcome in advanced coloreetal cancer patients treated with platinum-based chemotherapy.Clin Adv Hematol Oncol,2003,1(3):162.

共引文献5

同被引文献8

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部